RU2015116933A - THE IMPROVED METHOD FOR CLEANING MILK LACTOFERRIN AND ITS PRODUCTS - Google Patents
THE IMPROVED METHOD FOR CLEANING MILK LACTOFERRIN AND ITS PRODUCTS Download PDFInfo
- Publication number
- RU2015116933A RU2015116933A RU2015116933A RU2015116933A RU2015116933A RU 2015116933 A RU2015116933 A RU 2015116933A RU 2015116933 A RU2015116933 A RU 2015116933A RU 2015116933 A RU2015116933 A RU 2015116933A RU 2015116933 A RU2015116933 A RU 2015116933A
- Authority
- RU
- Russia
- Prior art keywords
- lactoferrin
- milk
- treatment
- growth factors
- rnase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 24
- 235000013336 milk Nutrition 0.000 title claims abstract 21
- 239000008267 milk Substances 0.000 title claims abstract 21
- 210000004080 milk Anatomy 0.000 title claims abstract 21
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract 19
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract 19
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract 19
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract 19
- 229940078795 lactoferrin Drugs 0.000 title claims abstract 19
- 238000004140 cleaning Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 238000001914 filtration Methods 0.000 claims abstract 19
- 239000003102 growth factor Substances 0.000 claims abstract 13
- 102000006382 Ribonucleases Human genes 0.000 claims abstract 11
- 108010083644 Ribonucleases Proteins 0.000 claims abstract 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 10
- 239000000706 filtrate Substances 0.000 claims abstract 10
- 239000011780 sodium chloride Substances 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000036541 health Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 1
- 208000009206 Abruptio Placentae Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 1
- 206010070531 Foetal growth restriction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 208000006816 Neonatal Sepsis Diseases 0.000 claims 1
- 206010048685 Oral infection Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 208000030941 fetal growth restriction Diseases 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000007413 intestinal health Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000018773 low birth weight Diseases 0.000 claims 1
- 231100000533 low birth weight Toxicity 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 208000015994 miscarriage Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 201000008532 placental abruption Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 239000000718 radiation-protective agent Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 208000000995 spontaneous abortion Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Abstract
1. Способ очистки лактоферрина молока, включающий фильтрацию молока через фильтр с НОММ 30 кДа или более с целью разделения его на фракцию ультраконцентрата, содержащую лактоферрин, и фракцию фильтрата, содержащую факторы роста и/или РНКазы, причем во время фильтрации молоко подвергают обработке солью таким образом, что в фильтрат попадают факторы роста и/или РНКазы, при этом обработка солью включает поддержание молока или лактоферрина в течение фильтрации при концентрации соли, составляющей по меньшей мере 0,2 М NaCl или эквивалента, или проводимости по меньшей мере 20 мСм.2. Способ по п. 1, отличающийся тем, что фильтр имеет НОММ 50 кДа или менее.3. Способ по любому из пп. 1 или 2, отличающийся тем, что обработка солью длится по меньшей мере 4 часа.4. Способ по любому из пп. 1 или 2, отличающийся тем, что фильтрацию осуществляют при 50-70 °С.5. Способ очистки лактоферрина молока, при этом способ включает фильтрацию молока через фильтр с НОММ 30 кДа или более с целью разделения его на фракцию ультраконцентрата, содержащую лактоферрин. и фракцию фильтрата, содержащую факторы роста и/или РНКазы, причем перед и/или во время фильтрации молоко подвергают обработке солью, способствующей дезагрегации или диссоциации любой массы РНКаз или факторов роста таким образом, что факторы роста и/или РНКазы попадают в фильтрат, при этом обработка солью включает поддержание молока или лактоферрина в течение фильтрации при концентрации соли, составляющей по меньшей мере 0,2 М NaCl или эквивалента, или проводимости по меньшей мере 20 мСм.6. Способ по п. 5, отличающийся тем, что фильтр имеет НОММ 50 кДа или менее.7. Способ по любому из пп. 5 или 6, отличающийся тем, что обработка солью длится по меньшей мере 4 часа.8. Способ по1. A method of purifying milk lactoferrin, comprising filtering milk through a filter with HOMM of 30 kDa or more in order to separate it into an ultraconcentrate fraction containing lactoferrin and a filtrate fraction containing growth factors and / or RNase, and during filtration, the milk is subjected to salt treatment with such in such a way that growth factors and / or RNases enter the filtrate, and salt treatment involves maintaining milk or lactoferrin during filtration at a salt concentration of at least 0.2 M NaCl or equivalent, or At least 20 mS. 2. The method according to claim 1, characterized in that the filter has a HOMM of 50 kDa or less. 3. The method according to any one of paragraphs. 1 or 2, characterized in that the salt treatment lasts at least 4 hours. The method according to any one of paragraphs. 1 or 2, characterized in that the filtration is carried out at 50-70 ° C. 5. A method for purifying milk lactoferrin, the method comprising filtering milk through a filter with a HOMM of 30 kDa or more in order to separate it into a fraction of an ultraconcentrate containing lactoferrin. and a filtrate fraction containing growth factors and / or RNase, and before and / or during filtration, the milk is subjected to a salt treatment to disaggregate or dissociate any mass of RNase or growth factors so that growth factors and / or RNase enter the filtrate, this salt treatment involves maintaining milk or lactoferrin during filtration at a salt concentration of at least 0.2 M NaCl or equivalent, or a conductivity of at least 20 mS. 6. A method according to claim 5, characterized in that the filter has an HOMM of 50 kDa or less. The method according to any one of paragraphs. 5 or 6, characterized in that the salt treatment lasts at least 4 hours. Method according
Claims (14)
1. Способ очистки лактоферрина молока, включающий фильтрацию молока через фильтр с НОММ 30 кДа или более с целью разделения его на фракцию ультраконцентрата, содержащую лактоферрин, и фракцию фильтрата, содержащую факторы роста и/или РНКазы, причем во время фильтрации молоко подвергают обработке солью таким образом, что в фильтрат попадают факторы роста и/или РНКазы, при этом обработка солью включает поддержание молока или лактоферрина в течение фильтрации при концентрации соли, составляющей по меньшей мере 0,2 М NaCl или эквивалента, или проводимости по меньшей мере 20 мСм.
1. A method of purifying milk lactoferrin, comprising filtering milk through a filter with HOMM of 30 kDa or more in order to separate it into an ultraconcentrate fraction containing lactoferrin and a filtrate fraction containing growth factors and / or RNase, and during filtration, the milk is subjected to salt treatment with such in such a way that growth factors and / or RNases enter the filtrate, and salt treatment involves maintaining milk or lactoferrin during filtration at a salt concentration of at least 0.2 M NaCl or equivalent, or at least 20 ms.
2. Способ по п. 1, отличающийся тем, что фильтр имеет НОММ 50 кДа или менее.
2. The method according to p. 1, characterized in that the filter has a HOMM of 50 kDa or less.
3. Способ по любому из пп. 1 или 2, отличающийся тем, что обработка солью длится по меньшей мере 4 часа.
3. The method according to any one of paragraphs. 1 or 2, characterized in that the salt treatment lasts at least 4 hours.
4. Способ по любому из пп. 1 или 2, отличающийся тем, что фильтрацию осуществляют при 50-70 °С.
4. The method according to any one of paragraphs. 1 or 2, characterized in that the filtration is carried out at 50-70 ° C.
5. Способ очистки лактоферрина молока, при этом способ включает фильтрацию молока через фильтр с НОММ 30 кДа или более с целью разделения его на фракцию ультраконцентрата, содержащую лактоферрин. и фракцию фильтрата, содержащую факторы роста и/или РНКазы, причем перед и/или во время фильтрации молоко подвергают обработке солью, способствующей дезагрегации или диссоциации любой массы РНКаз или факторов роста таким образом, что факторы роста и/или РНКазы попадают в фильтрат, при этом обработка солью включает поддержание молока или лактоферрина в течение фильтрации при концентрации соли, составляющей по меньшей мере 0,2 М NaCl или эквивалента, или проводимости по меньшей мере 20 мСм.
5. A method for purifying milk lactoferrin, the method comprising filtering milk through a filter with a HOMM of 30 kDa or more in order to separate it into a fraction of an ultraconcentrate containing lactoferrin. and a filtrate fraction containing growth factors and / or RNase, and before and / or during filtration, the milk is subjected to a salt treatment to disaggregate or dissociate any mass of RNase or growth factors so that growth factors and / or RNase enter the filtrate, this salt treatment involves maintaining milk or lactoferrin during filtration at a salt concentration of at least 0.2 M NaCl or equivalent, or a conductivity of at least 20 mS.
6. Способ по п. 5, отличающийся тем, что фильтр имеет НОММ 50 кДа или менее.
6. The method according to p. 5, characterized in that the filter has a HOMM of 50 kDa or less.
7. Способ по любому из пп. 5 или 6, отличающийся тем, что обработка солью длится по меньшей мере 4 часа.
7. The method according to any one of paragraphs. 5 or 6, characterized in that the salt treatment lasts at least 4 hours.
8. Способ по любому из пп. 5 или 6, отличающийся тем, что фильтрация происходит при 50-70 °С.
8. The method according to any one of paragraphs. 5 or 6, characterized in that the filtration occurs at 50-70 ° C.
9. Способ очистки лактоферрина молока, включающий фильтрацию молока через фильтр с НОММ 30 кДа или более с целью разделения его на фракцию ультраконцентрата, содержащую лактоферрин, и фракцию фильтрата, содержащую факторы роста и/или РНКазы, причем перед и/или во время фильтрации молоко подвергают обработке солью, способствующей отделению любых РНКазы или факторов роста от мембраны, вследствие чего факторы роста и/или РНКазы попадают в фильтрат, при этом обработка солью включает поддержание молока или лактоферрина в течение фильтрации при концентрации соли, составляющей по меньшей мере 0,2 М NaCl или эквивалента, или проводимости по меньшей мере 20 мСм.
9. A method for purifying milk lactoferrin, comprising filtering milk through a filter with HOMM of 30 kDa or more in order to separate it into an ultraconcentrate fraction containing lactoferrin and a filtrate fraction containing growth factors and / or RNase, and before and / or during filtration, milk subjected to treatment with a salt, which facilitates the separation of any RNase or growth factors from the membrane, as a result of which growth factors and / or RNase enter the filtrate, and the salt treatment involves maintaining milk or lactoferrin during filtration during a salt concentration of at least 0.2 M NaCl or equivalent, or a conductivity of at least 20 mS.
10. Способ по п. 9, отличающийся тем, что фильтр имеет НОММ 50 кДа или менее.
10. The method according to p. 9, characterized in that the filter has a HOMM of 50 kDa or less.
11. Способ по любому из пп. 9 или 10, отличающийся тем, что обработка солью длится по меньшей мере 4 часа.
11. The method according to any one of paragraphs. 9 or 10, characterized in that the salt treatment lasts at least 4 hours.
12. Способ по любому из пп. 9 или 10, отличающийся тем, что фильтрация происходит при 50-70 °С.
12. The method according to any one of paragraphs. 9 or 10, characterized in that the filtration occurs at 50-70 ° C.
13. Лактоферрин, полученный с помощью способа по любому из пп. 1-12.
13. Lactoferrin obtained using the method according to any one of paragraphs. 1-12.
14. Применение лактоферрина по п. 13 в качестве противоракового, противовирусного, антимикробного или противовоспалительного агента, для лечения пролиферативных расстройств, таких как рак, особенно включающих твердые опухоли, для лечения злокачественных новообразований и гиперпролиферативных заболеваний, для лечения костных заболеваний путем стимуляции остеогенеза, для лечения вирусных или микробных инфекций, для лечения ран роговицы, для повышения иммунитета, для лечения В-клеточной неходжкинской лимфомы, для лечения септического шока, для улучшения здоровья кишечника путем повышения числа бифидобактерий при снижении количества E.coli, Streptococcus и Clostridium, для лечения ВЗК, для стимулирования иммунитета и сопротивляемости к болезням, для управления системными воспалениями, чтобы предотвратить отторжение трансплантата органа и реакцию "трансплантат против хозяина", для улучшения здоровья матери и плода, для улучшения здоровья нейронов и развития кишечника новорожденного, чтобы уменьшить вероятность ассоциированных с беременностью осложнений, таких как преэклампсия, преждевременные роды, гестационный диабет, выкидыш, внутриутробная гибель плода, преждевременные роды, низкий вес при рождении, отслойка плаценты и внутриутробная задержка роста, особенно у женщин с гипоферремией или железодефицитной анемией, для лечения дефицита железа и анемии, особенно у беременных женщин, для профилактики неонатального сепсиса у недоношенных новорожденных, для заживления ран, для облегчения формирования биопленки, для лечения инфекций полости рта, включая периодонтит, для лечения диабетических язв, при лечении муковисцидоза, для уменьшения боли, для лечения протеинурии, для стимуляции роста клеток кожи, в качестве радиопротекторного агента, при лечении инфекций мочевыводящих путей, при лечении дегенеративных заболеваний суставов, при лечении диабета, при лечении респираторных расстройств, для сокращения циркулирующего холестерина, при сосудистом воспалении, атеросклерозе и сердечно-сосудистых заболеваниях, а также все другие применения лактоферрина, известные специалистам в данной области техники.
14. The use of lactoferrin according to claim 13 as an anticancer, antiviral, antimicrobial or anti-inflammatory agent, for the treatment of proliferative disorders, such as cancer, especially including solid tumors, for the treatment of malignant neoplasms and hyperproliferative diseases, for the treatment of bone diseases by stimulating osteogenesis, for for treating viral or microbial infections, for treating corneal wounds, for enhancing immunity, for treating B-cell non-Hodgkin lymphoma, for treating septic sho a) to improve intestinal health by increasing the number of bifidobacteria while reducing the number of E. coli, Streptococcus and Clostridium, to treat IBD, to stimulate immunity and resistance to diseases, to control systemic inflammation, to prevent organ transplant rejection and the transplant versus host reaction , to improve maternal and fetal health, to improve neuronal health and the development of the intestines of the newborn, to reduce the likelihood of pregnancy-related complications, such as preeclampsia preterm birth, gestational diabetes, miscarriage, prenatal death, premature birth, low birth weight, placental abruption and intrauterine growth retardation, especially in women with hypoferremia or iron deficiency anemia, for the treatment of iron deficiency and anemia, especially in pregnant women, for the prevention neonatal sepsis in premature infants, for wound healing, to facilitate the formation of biofilms, for the treatment of oral infections, including periodontitis, for the treatment of diabetic ulcers, in the treatment of cystic fibrosis idosis, to reduce pain, to treat proteinuria, to stimulate skin cell growth, as a radioprotective agent, in the treatment of urinary tract infections, in the treatment of degenerative joint diseases, in the treatment of diabetes, in the treatment of respiratory disorders, to reduce circulating cholesterol, with vascular inflammation , atherosclerosis and cardiovascular diseases, as well as all other uses of lactoferrin known to those skilled in the art.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012904391A AU2012904391A0 (en) | 2012-10-08 | Improved process for purifying milk proteins and products thereof | |
AU2012904391 | 2012-10-08 | ||
AU2013204858 | 2013-04-12 | ||
AU2013204858A AU2013204858B2 (en) | 2012-10-08 | 2013-04-12 | Improved process for purifying milk proteins and products thereof |
PCT/AU2013/001152 WO2014056025A1 (en) | 2012-10-08 | 2013-10-08 | Improved process for purifying lactoferrin from milk and products thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015116933A true RU2015116933A (en) | 2016-11-27 |
RU2683228C2 RU2683228C2 (en) | 2019-03-26 |
Family
ID=50476773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015116933A RU2683228C2 (en) | 2012-10-08 | 2013-10-08 | Improved method for purification of milk lactoferrin and products thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US10016487B2 (en) |
EP (1) | EP2904006A4 (en) |
JP (1) | JP6475163B2 (en) |
KR (1) | KR20150068404A (en) |
CN (1) | CN104768971B (en) |
AU (1) | AU2013204858B2 (en) |
BR (1) | BR112015007674A2 (en) |
CA (1) | CA2886892A1 (en) |
IN (1) | IN2015DN02971A (en) |
NZ (1) | NZ631826A (en) |
RU (1) | RU2683228C2 (en) |
WO (1) | WO2014056025A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013204858B2 (en) | 2012-10-08 | 2015-06-25 | Saputo Dairy Australia Pty Limited | Improved process for purifying milk proteins and products thereof |
CN106215174A (en) * | 2016-08-04 | 2016-12-14 | 无锡科捷诺生物科技有限责任公司 | A kind of formulation preparation method of human lactoferrin |
JP7370224B2 (en) * | 2019-11-08 | 2023-10-27 | ライオン株式会社 | Enteric-coated preparation containing lactoferrin |
FR3115037A1 (en) * | 2020-10-12 | 2022-04-15 | Compagnie Laitiere Europeenne | Process for purification of cationic protein fraction and fraction thus obtained |
CN113278063A (en) * | 2021-05-13 | 2021-08-20 | 上海仁统生物科技中心 | Method for obtaining lactoferrin from colostrum by ultrafiltration |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2584727B1 (en) * | 1985-07-11 | 1988-06-17 | Roussel Uclaf | PROCESS FOR EXTRACTING MILK PROTEINS, PRODUCTS, APPLICATION OF THE PROCESS, AND PHARMACEUTICAL COMPOSITIONS |
US5221734A (en) | 1987-10-01 | 1993-06-22 | Ciba-Geigy Corporation | Process for preparing a polypeptide growth factor for milk |
GB8729031D0 (en) * | 1987-12-11 | 1988-01-27 | Express Foods Group Ltd | Isolation of immunoglobulin rich fraction from whey |
JP2686831B2 (en) | 1989-09-22 | 1997-12-08 | 雪印乳業株式会社 | Method for separating, purifying, and collecting iron-binding protein |
EP0620709B1 (en) * | 1992-01-15 | 1995-10-18 | Campina Melkunie B.V. | Process for isolating lactoferrin and lactoperoxidase from milk and milk products |
JPH05202098A (en) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | Production of physiologically active substance from lactic material |
US5756680A (en) * | 1994-01-05 | 1998-05-26 | Sepragen Corporation | Sequential separation of whey proteins and formulations thereof |
JPH09509165A (en) * | 1994-02-16 | 1997-09-16 | ファーミング ベスローテン フェンノートシャップ | Separation of lactoferrin from milk |
NL1005677C2 (en) * | 1997-03-27 | 1998-09-29 | Campina Melkunie Bv | Method for recovering growth factors, or a composition containing one or more growth factors, from milk or a derivative thereof. |
ATE420108T1 (en) * | 2001-07-20 | 2009-01-15 | Campina Bv | METHOD FOR PRODUCING PREPARATIONS FROM DAIRY PRODUCTS CONTAINING GROWTH FACTORS (TGF-BETA AND IGF-1), LACTOPEROXIDASE AND IMMUNOGLOBULINS WITH LOW MUTUAL IMPURITY |
US6875459B2 (en) * | 2001-09-10 | 2005-04-05 | Henry B. Kopf | Method and apparatus for separation of milk, colostrum, and whey |
NZ535784A (en) * | 2002-03-07 | 2006-02-24 | Upfront Chromatography As | A process of isolating lactoferrin |
FR2841747B1 (en) * | 2002-07-02 | 2004-08-20 | Cie Laitiere Europeenne | MILK PROTEIN ISOLATE AND PROCESS FOR ITS PREPARATION |
GB0313892D0 (en) * | 2003-06-16 | 2003-07-23 | Hannah Res Inst | Control of lactation |
US20050208638A1 (en) * | 2004-03-22 | 2005-09-22 | Chao Wu | Process for preparing bioactive protein-enriched whey products |
EP1789073A4 (en) | 2004-09-14 | 2011-06-08 | Nexcell Biosciences Inc | Isolation of growth and differentiating factors from colostrum |
EP1940426A4 (en) * | 2005-09-09 | 2009-10-28 | Murray Goulburn Coop Co Ltd | Composition of whey growth factor extract for reducing muscle inflammation |
FR2901796A1 (en) | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | PROCESS FOR EXTRACTING ONE OR MORE PROTEINS PRESENT IN MILK |
JP5276004B2 (en) * | 2006-11-10 | 2013-08-28 | マリー ゴールバーン シーオー−オペレイティブ シーオー.リミテッド | Method for preparing angiogenin |
RU2538654C2 (en) * | 2008-05-14 | 2015-01-10 | Эгрикалчер Виктория Сервисиз Пти Лтд | Milk fractions enriched with angiogenine |
PL2391225T3 (en) | 2009-01-28 | 2020-11-16 | Jean-Paul Perraudin | Method for production of lactoferrin |
AU2011283472B2 (en) | 2010-07-30 | 2014-02-13 | Morinaga Milk Industry Co., Ltd. | Antimicrobial activity enhancing agent |
AU2013204858B2 (en) | 2012-10-08 | 2015-06-25 | Saputo Dairy Australia Pty Limited | Improved process for purifying milk proteins and products thereof |
-
2013
- 2013-04-12 AU AU2013204858A patent/AU2013204858B2/en active Active
- 2013-10-08 CN CN201380055328.7A patent/CN104768971B/en not_active Expired - Fee Related
- 2013-10-08 KR KR1020157010356A patent/KR20150068404A/en active IP Right Grant
- 2013-10-08 US US14/434,324 patent/US10016487B2/en active Active
- 2013-10-08 RU RU2015116933A patent/RU2683228C2/en not_active IP Right Cessation
- 2013-10-08 NZ NZ631826A patent/NZ631826A/en not_active IP Right Cessation
- 2013-10-08 CA CA2886892A patent/CA2886892A1/en not_active Abandoned
- 2013-10-08 JP JP2015534883A patent/JP6475163B2/en not_active Expired - Fee Related
- 2013-10-08 EP EP13844731.3A patent/EP2904006A4/en not_active Withdrawn
- 2013-10-08 BR BR112015007674A patent/BR112015007674A2/en not_active Application Discontinuation
- 2013-10-08 WO PCT/AU2013/001152 patent/WO2014056025A1/en active Application Filing
-
2015
- 2015-04-09 IN IN2971DEN2015 patent/IN2015DN02971A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150068404A (en) | 2015-06-19 |
EP2904006A1 (en) | 2015-08-12 |
AU2013204858B2 (en) | 2015-06-25 |
US20150315264A1 (en) | 2015-11-05 |
AU2013204858A1 (en) | 2014-04-24 |
IN2015DN02971A (en) | 2015-09-18 |
US10016487B2 (en) | 2018-07-10 |
NZ631826A (en) | 2017-08-25 |
CA2886892A1 (en) | 2014-04-17 |
CN104768971A (en) | 2015-07-08 |
BR112015007674A2 (en) | 2017-07-04 |
RU2683228C2 (en) | 2019-03-26 |
JP2015536905A (en) | 2015-12-24 |
CN104768971B (en) | 2017-12-05 |
WO2014056025A1 (en) | 2014-04-17 |
EP2904006A4 (en) | 2016-04-06 |
WO2014056025A8 (en) | 2015-05-14 |
JP6475163B2 (en) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015116933A (en) | THE IMPROVED METHOD FOR CLEANING MILK LACTOFERRIN AND ITS PRODUCTS | |
Colella | A critical reconsideration of biomedical and veterinary applications of natural zeolites | |
JP2015536905A5 (en) | ||
JP6141997B2 (en) | Chlorine dioxide prepared and used in methods of acting on mammalian stem cells and applications of drugs acting on mammalian stem cells | |
JP7426927B2 (en) | Iron complex compounds for therapeutic use | |
JP6410229B2 (en) | Hydrolyzed eggshell membrane powder and method for producing the same | |
RU2429865C1 (en) | Agent exhibiting repairative and wound healing action | |
KR20170080336A (en) | Radish, lotus root and a red bit alcoholic extract consisting of anti-inflammatory composition | |
CN102041212A (en) | Method for preparing pomegranate wine | |
RU2485133C2 (en) | Protein-polypeptide complex possessing tissue-specific regenerative-reparative and rejuvenating action on skin tissue, method for preparing it, and pharmaceutical composition thereof | |
JP2012107002A (en) | Stress reliever | |
CN110680906A (en) | Glucosamine bone glue peptide calcium granules | |
WO2010110223A1 (en) | Fucoidan having antitumor activity | |
DE4430041A1 (en) | Allergy-protective formula food | |
EP2600881A1 (en) | Natural medicinal compound | |
WO2012166005A1 (en) | Protein-polypeptide complex with a specific activity on skin tissue, process for preparing same and pharmaceutical composition on the basis thereof | |
JPS6154389B2 (en) | ||
CN104355989A (en) | Method for preparing magnesium malate | |
RU2436569C1 (en) | Method of treating retained placenta in cows | |
CN105568675B (en) | A kind of preparation method of H-type carboxymethyl chitosan fiber | |
CN114365846A (en) | Hyaluronic acid oral liquid and preparation method and application thereof | |
CN102000134B (en) | Medicine for external use for treating skin inflammation | |
JP2016500662A5 (en) | ||
RU2015116931A (en) | IMPROVED METHOD FOR CLEANING MILK GROWTH FACTORS AND THEIR PRODUCTS | |
RU2553633C1 (en) | Ointment for septic and open wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200221 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201009 |